1.55
-3.73%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cantargia
Its shares trade on Nasdaq Stockholm under the ticker CANTA.ST. It has been listed since 17 March 2015. In the fiscal year to 31 December 2025, it reported revenue of SEK 316.7m and net income of SEK 147.0m. At that date it held total assets of SEK 296.7m and shareholders' equity of SEK 265.9m.
Cantargia AB is a holding company, which engages in the development of antibody-based cancer treatment. The company is headquartered in Lund, Skane. The company went IPO on 2015-03-17. The firm is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Mar 2015
- Employees
- 18
- Website
- cantargia.com ↗
Leadership
Pay as last reported
- Dr. Magnus PerssonIndependent Chairman of the Board, since 2016SEK 815,000
- Dr. Hilde SteinegerChief Executive Officer
- Mr. Patrik RenbladChief Financial Officer
- Ms. Susanne LagerlundVice President - Regulatory Affairs
- Mr. David LibergVice President - Research
- Mr. Nedjad LosicVice President - Biometrics
- Mr. Peter MadsenVice President - CMC
- Mr. Lars ThorssonVice President - Clinical Development
- Mr. Ton BerkienChief Business Officer
- Dr. Wolfram DempkeChief Medical Officer
- Mr. Damian MarronNon-Executive Director, since 2021SEK 330,000
- Dr. Flavia BorelliniIndependent DirectorSEK 520,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cantargia AB possesses several strong aspects that contribute to its competitive advantage in the market. One of its key strengths is its strong and experienced management team, comprising industry experts with a deep understanding of the biotechnology sector. This enables the company to make informed strategic decisions and navigate complex challenges effectively.
- Another significant strength of Cantargia AB is its robust research and development capabilities. The company invests heavily in cutting-edge technologies and innovation, allowing them to develop a diverse pipeline of novel therapeutic candidates. This diverse portfolio minimizes dependence on a single product and enhances the potential for revenue growth.
- In addition, Cantargia AB benefits from a strong intellectual property portfolio, which includes patents protecting its innovative products and technologies. This provides the company with a competitive edge, as it can prevent unauthorized usage of its inventions and foster a stronger market position.
Weaknesses
- Despite its strengths, Cantargia AB also faces certain weaknesses that need to be addressed. One such weakness is the company's limited financial resources. While it has successfully secured funding through partnerships and collaborations, its financial flexibility may be restricted compared to larger competitors. This could impact the company's ability to accelerate product development or expand market presence.
- Another weakness is Cantargia AB's relatively small size and limited market reach. As a smaller biotechnology firm, it may face challenges in establishing a strong brand presence and capturing market share. To mitigate this weakness, the company needs to focus on effective marketing strategies and building strong relationships with key stakeholders in the industry.
Opportunities
- Cantargia AB operates in an industry with vast opportunities for growth and innovation. One of the key opportunities lies in the increasing demand for targeted therapies. With its strong research capabilities, Cantargia AB is well-positioned to develop and commercialize innovative therapies that address unmet medical needs in various disease areas.
- Moreover, the company can leverage strategic partnerships and collaborations to expand its market reach. Collaborating with larger pharmaceutical companies can provide access to additional resources, expertise, and global distribution channels, thereby accelerating the commercialization and adoption of its therapeutic candidates.
Threats
- Cantargia AB faces several threats that could potentially hinder its growth and success. One significant threat is the intense competition within the biotechnology industry. The presence of numerous established and emerging competitors means that Cantargia AB must continuously innovate and differentiate its products to stay ahead in the market.
- Additionally, regulatory challenges and stringent approval processes pose a threat to the timely launch of Cantargia AB's products. Delays in regulatory approvals can significantly impact the company's revenue generation and market penetration, potentially giving competitors an advantage.
- Lastly, economic uncertainties and market fluctuations can negatively impact the biotechnology sector as a whole, affecting investor confidence and funding availability. Cantargia AB must remain agile in the face of these external factors and adapt its strategies accordingly to mitigate potential risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.